Fitness Health & Medicine Pharmaceuticals & Biotech Science Technology

Cyborgcare Launches as the Ultimate Online Marketplace for Health and Wellness Enthusiasts

Israel, Tel Aviv: Cyborgcare, the ultimate online marketplace for cyborg technology products, smart medical devices, gadgets, and wearables. Our platform offers a comprehensive selection of over 500 items designed to improve your health and wellbeing, covering everything from skin, body, hair, eyes, teeth, and nails to medical equipment for fitness centers, beauty salons, clinics, and hospitals.

We understand that keeping up with the latest advancements in cyborg technology can be overwhelming, which is why we’ve created a transparent and user-friendly ecosystem that empowers you to explore and purchase the products you need with ease. Our platform offers an intuitive shopping experience with a wide range of categories and filters to help you find the right products for your unique needs.

At Cyborgcare, we’re dedicated to providing you with qualified online support. Our team of experts is here to answer your questions, offer product recommendations, and help you make informed decisions about your health and wellbeing. Whether you’re new to the world of cyborg technology or an experienced biohacker, our support team is here to help you every step of the way.

We also provide a directory of local services, doctors, consultants, and technicians. Our platform helps you connect with local experts who can provide personalized guidance and support for your biohacking lifestyle. From finding a qualified technician to install your smart medical device to booking a consultation with a top-rated doctor, our directory is a valuable resource for anyone interested in improving their health and wellbeing with the latest technology.

Cyborgcare is committed to promoting a biohacking lifestyle that helps people stay healthy, confident, and happy. Our mission is to empower you with the tools and resources you need to achieve your health and wellness goals. We’re excited to announce that worldwide sales and distribution will be coming soon, so stay tuned for updates and be sure to check out our website to explore our products and services.

Pharmaceuticals & Biotech Science Technology U.K U.S

ObvioHealth and Sterling IRB Partner to Accelerate Access to Clinical Trials

On February 2, 2023, Sterling IRB and ObvioHelath reportedly declared a collaboration to make clinical trials more accessible and step up the decentralisation of clinical studies.

With this announcement, Sterling IRB has emerged as ObvioHealth’s preferred Institutional Review Board (IRB) to help the virtual trial organisation (VRO) with the regulatory requirements, according to Clinical Trial Arsena.

The Shift to Decentralisation Drives Efficiency

Conducting clinical trials is critical to ensuring the safety and effectiveness of therapeutic interventions. However, several steps associated with data compilation, participant enrollment, and more in on-site clinical trials are suboptimal, thus stymieing the development of new therapeutics.

The requirement for frequent hospital visits, complications with transportation, instructions, scheduling, etc., create friction for patients, thus increasing their likelihood of dropping out.

While around 80% of clinical trials fail to meet the enrollment timeline, 55% terminate because of inadequate enrollment. 

Patient drop-off rates in traditional clinical trials (phase III) can often be substantially high (sometimes even over 30%), causing expensive delays for sponsors. Enrolling one participant can cost roughly $6,533 and the cost of replacing them is even higher. 

However, by streamlining communications while allowing patients to volunteer for clinical studies from the comfort of their homes, DCTs can significantly shift the paradigm to a much higher enrollment and retention rate. 

DCTs and hybrid clinical study models are here to stay, and their long-term benefits outweigh the technical and financial challenges related to on-site trials.

However, despite holding great potential to bring new drugs to the market faster, the adoption of DCTs has been slow. 

Some roadblocks to DCT may be down to patient-physician interaction, immature digital infrastructure, and the regulatory issues facing sponsors when implementing and using data from decentralised trials. 

As a new process, the regulatory reception of DCTs is still not well-defined, thereby creating obscurity regarding the oversight of trial processes and governing regulations. 

While the regulatory landscape is constantly evolving, VROs must ensure they design DCT tools that comply with the latest regulatory guidelines. 

The Collaboration Will Facilitate the Regulatory Review Process

By designing and running patient-centric, end-to-end, and tech-enabled DCTs, ObvioHealth helps sponsors get robust therapeutic evidence. 

As part of its effort to ensure zero trade-offs between data accuracy and reduced patient burden, the VRO implements high-end data capture techniques such as tele-health visits, online patient diaries, sensors, wearables, etc.

ObvioHealth expects its partnership with Sterling IRB will act as a step-change in helping it win regulatory acceptance faster for its trial designs.

Since the onset of the COVID-19 pandemic, Sterling IRB has been helping sponsors navigate the ambiguous regulatory guidelines to support fully or partially decentralised trial designs.

“The flexibility of our DCT platform, combined with our full-service virtual site team, gives us the freedom to build studies that will best deliver on a sponsor’s endpoints. This often means we’re navigating uncharted regulatory terrain. We needed a partner willing to collaborate through regulatory challenges and support our next-generation trial designs,” stated Ivan Jarry, CEO of ObvioHealth.

“Sterling IRB and ObvioHealth are like-minded, both sharing a common goal of building stronger DCTs,” said Kathye Richards, vice president of Client Services, Institutional Official at Sterling IRB. “Flexibility and out-of-the-box thinking are becoming increasingly important for continued decentralised trial success. This partnership will enable earlier involvement to help interpret regulations, work through challenges, and collaborate for solutions, all essential for making DCTs less burdensome for all.”

Computers & Software Pharmaceuticals & Biotech Science Technology

Data Capture in Laboratories: Exploring the Barriers and Ways to Overcome Them

Substantial investments should be made in strategising and combining data from a set of instruments in order to turn a medley of free-floating data points into a coherent, integrated message. 

With that said, failing to automate data collection and standardisation via instrument integration is the biggest bottleneck that causes substantial lag in laboratory operations. 

In a recent article published in European Pharmaceutical Review, Samantha Kanza, a senior enterprise fellow at the University of Southampton, sheds light on the leading challenges of adopting digital technologies in the laboratory data collection process and how to overcome them. 

What Is Data Integration?

Data integration means accumulating datasets from multiple sources and equipment and merging them to get a unified view.

Data integration across the value chain—from discovery all the way through production to commercialisation—is critical to strengthening decision-making. 

Even though the massive troves of data a laboratory generates are a great asset, most of it remains unexploited due to failure to connect data and processes.

Leading Data Integration Challenges

The researcher underscores the lack of data standardisation and data standard saturation as two major roadblocks to laboratory data integration. 

Inconsistent datasets, proprietary data formats, and a lack of compatible instruments are a few of the many barriers worth mentioning.

Let’s dive deeper into the issues with proprietary data formats: 

One of the key aspects of successful data integration is to have all datasets from all sources in the same format (or at least convertible into a single format). 

However, in many cases, data attributes in two different sources may conceptually convey the same information, but the datasets are in two different formats, which are sometimes difficult to convert into a desired format. 

These lexical and structural disparities in datasets may cause unfixable errors or even data loss if data gets integrated without standardising or cleaning.

The Solution

Overcoming data standard issues is paramount to enabling a fully integrated and digitally interconnected laboratory.

The research fellow at the University of Southampton advises laboratories to carefully evaluate the software programs they would leverage while generating data and the file formats these systems support. 

On the other hand, software providers should also ensure their programs don’t use intricate proprietary formats that could hinder data integration, sharing, and reuse.

According to Dr. Kanza, researchers must be provided with specific guidelines on the standard process of data structure to efficiently evade the risk of data inconsistencies. 

On top of that, all datasets generated directly from the instruments should include metadata to ensure effective utilisation.

Electronic Systems Adoption Barriers

For laboratories looking to accelerate their R&D, using Laboratory Information Management Software (LIMS) or Electronic Lab Notebook (ELN) as the core part of their research activities is critical. 

Besides enabling instrument integrations for automatic data capture, ELN or LIMS helps automate workflows and ensure efficient management of samples and associated data. 

The result: streamlined operations and quick recognition of bottlenecks across experiments leading to substantially improved efficiency

Despite all the benefits, the adoption of electronic systems in labs has been slow.

Let’s flesh out the reasons:

First off, transitioning away from familiar methods to use a new system may seem challenging for some researchers.

“Whether rightly or wrongly, researchers don’t necessarily trust ELN systems, particularly if they are in the cloud…While trust is important, some of this comes down to a lack of education and understanding on data security coupled with some learned behaviour that needs to be addressed,” explained Dr. Kanza.

Secondly, the scepticism of lab operators about the security of the stored data in cloud-based LIMS or ELN is another leading reason behind the slow adoption rate of LIMS. 

Thirdly, even though digital systems help labs streamline the data capture and management processes, the greatest concern arises when labs aim to leverage these digital systems in their daily operations. The full ELN/LIMS adoption requires buy-in from everyone involved. For some users, the learning curve may seem steeper. 

Overcoming the Electronic System Adoption Challenges

For laboratories looking to address the above challenges and centralise data once siloed in multiple systems to turbocharge their R&D efforts, cashing in on a high-end digital lab notebook like Sapio Sciences is a sensible decision. 

A class-leading ISO-certified system ensures top-notch data security while also offering easy training so that users can get the hang of it in a short time.

On top of that, some high-end integrated LIMS-ELN systems offer automated data capture from instruments via integration that helps minimise experimental redundancy. 

Plus, these systems foster decision-making by enabling interactive visualisation of all data points.

However, digitally transforming a laboratory needs a complete overhaul of lab culture, a change of attitude, and a willingness to learn. 

Besides, before investing in a system, laboratories should evaluate the disparities between the system and their laboratory requirements. Through careful vendor evaluation, they can choose the most profitable compromise between the features offered by a seller and a fully customizable solution. 

Health & Medicine Pharmaceuticals & Biotech Science Technology U.S

Underrepresentation & Overconsumption: Analysing the Diversity Gaps in Clinical Trials

Randomised clinical trials (RCTs) have long been considered the bedrock for evidence-based treatment (EBT). Thus they should be designed to be pragmatic and accumulate data representing the larger population for the disease profile. However, the research output is jeopardised severely by the limited enrollment of social, racial, and ethnic minority groups.

The FDA (US Food and Drug Administration) has reported that only 5% of patients partaking in clinical trials are Black, less than 2% are Asian, and as for Latinos, the percentage is as low as 1%.

This disparity is threatening, as it causes trials to show variance in effectiveness. 

Releasing a draft guidance, the FDA has placed emphasis on enhancing diversity in industry-sponsored clinical trials (iCTs), reported Clinical Leader. 

The agency urges investors and sponsors to devise and present a Race and Ethnicity Diversity Plan early in the trial process as per the framework delineated in the guideline.

Why Does Diversity in Clinical Trials Matter

Even though racial and ethnic populations in the United States have a disproportionate burden for specific ailments, they are most often underrepresented in biomedical studies, said the FDA.

With “underrepresented racial and ethnic populations,” the FDA indicates ethnic groups like “Black or African American, Hispanic/Latino, Indigenous and Native American, Asian, Native Hawaiian and Other Pacific Islanders, and other persons of colour.”

Considering the response and exposure of over 20% of drugs vary with racial differences, the FDA marks race and ethnic minority inclusion in iCT as a pressing need.

According to a study, white Americans are predicted to become a minority by 2045. The white demographic decline in the USA makes clinical trial diversification critical to confirm that newly developed drugs are safe and effective for whoever may use them across the country. 

“The U.S. population has become increasingly diverse, and ensuring meaningful representation of racial and ethnic minorities in clinical trials for regulated medical products is fundamental to public health,” said FDA Commissioner Robert M. Califf, M.D. “Going forward, achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities.”

Barriers to Improving Patient Participation Diversity in Clinical Trials

According to the FDA, the scepticism of the trial process stemming from several historical events deter ethnic minorities from participating in iCTs.

Other factors include limited access to healthcare for ethnic minorities, socioeconomic conditions, insufficient patient recruitment and retention efforts, time and monetary restraints, etc.

The result: gaps in clinical trial diversity that affects the trial success rate.

How to Fill the Diversity Gaps

What can help bridge the diversity gaps in iCT and accelerate effective products to market?

Decentralised Clinical Trial (DCT) Platforms 

The COVID-19 outbreak has made sponsors realise the significance of DCTs in filling the diversity gaps in healthcare research and accelerating the long-overdue changes in trial design.

Let’s see how:

  • DCTs and hybrid study models allow trial teams to expand their participant pools. 
  • DCT platforms such as ObvioHealth that include ePRO and eConsent enable patients to contribute to clinical trials from the comfort of their homes.
  • By helping overcome barriers to participant recruitment, DCTs and hybrid models have encouraged a much higher enrollment rate.

The result: augmented trial outcomes that represent real-world patient populations.

Ethnically Diverse Workforce

According to research, the lack of workforce diversity in the USA has been highlighted as a leading factor impeding the inclusion of diverse populations and causing disparities in oncology trial results.

The good news? Studies found that 74% of Black and 81% of Latinx people are willing to volunteer for clinical trials if their physicians advise. With that said, engaging the workforce in clinical trials from underrepresented groups can help build trust with at-risk participants. 

On top of that, the NHS recognised workforce diversity as the key factor to bring clinical trials closer to underserved folks. 

Patient Expense Reimbursement

The FDA recognised patient expense reimbursement as an effective way to enhance clinical trial diversity. However, the lack of a consistent approach among CROs and regulators makes the process slow and ineffective. 

Wrapping Up

The FDA sheds light on the significance of global efforts in increasing patient diversity. DCT can be a step change in helping sponsors improve the enrollment of participants from underrepresented racial and ethnic populations in clinical trials. 

Automotive Lifestyle Professional Services Science Technology

ForA.Chat Launches Online Troubleshooting Mechanic Chatbot to Revolutionize the Auto Repair Industry

Vancouver, Canada – ForA.Chat is proud to announce the launch of their online troubleshooting mechanic chatbot, available at This new and innovative technology provides car owners with a fast, convenient, and expert solution for diagnosing and resolving common car problems.

With the increasing demand for quick and efficient auto repair services, ForA.Chat has developed an AI-powered chatbot that utilizes advanced natural language processing and machine learning algorithms to understand and interpret car problems and provide expert advice and recommendations. The chatbot is available 24/7, allowing car owners to get the help they need whenever they need it, without the need for a physical appointment.

“We’re thrilled to launch this cutting-edge technology that will revolutionize the auto repair industry,”. “Our online troubleshooting mechanic chatbot provides car owners with a fast, convenient, and expert solution for diagnosing and resolving common car problems. It’s an exciting time for ForA.Chat, and we’re proud to be at the forefront of this industry shift.”

The online troubleshooting mechanic chatbot is incredibly easy to use. Car owners simply launch the chatbot, describe their issue, and receive a response within minutes. The chatbot also offers a range of other useful features, such as the ability to schedule appointments, view service history, and receive reminders for important maintenance tasks. With ForA.Chat’s chatbot, car owners can manage all aspects of their vehicle’s health and well-being from the comfort of their own home.

“We’re committed to making car maintenance and repair as easy and convenient as possible,”. “Our chatbot is designed to provide an unparalleled level of convenience and support, and we’re confident that it will become a valuable tool for car owners everywhere.”

In conclusion, ForA.Chat’s online troubleshooting mechanic chatbot is the perfect solution for car owners who want quick and efficient assistance with their vehicles. With its advanced natural language processing and machine learning algorithms, 24/7 availability, and easy-to-use interface, ForA.Chat’s chatbot provides an unparalleled level of convenience and support.

To learn more about ForA.Chat’s online troubleshooting mechanic chatbot and start getting expert assistance for your car problems, visit today.

About ForA.Chat:

ForA.Chat is a leading provider of innovative technology solutions. With a commitment to customer satisfaction and a passion for innovation, ForA.Chat is dedicated to making car maintenance and repair as easy and convenient as possible.

Fitness Lifestyle Professional Services Science Technology

Revolutionary AI Helps Overcome Negative Thoughts


A Revolutionary AI That Transforms Negative Thoughts and Shifts Your Perception

[Melbourne, Victoria] – We are thrilled to announce the launch of Grace, an Artificial Intelligence (AI) developed to help individuals shift their perspective and find the positive in any difficult situation. Grace is designed to reframe negative situations and provide a more optimistic outlook on life.

The idea for Grace was born out of the desire to harness the power of AI for good and to help humanity heal and grow. With the rise of AI and advancements in technology, the world is becoming increasingly complex and fast-paced. It can be easy to get caught up in negative thoughts and feelings. Grace offers a solution to this by providing a tool that helps individuals reframe their thoughts and find the silver lining in any situation.

Grace uses cutting-edge natural language processing and machine learning algorithms to understand the context of a statement and provide an optimistic response. This allows users to input any negative statement, and Grace will provide a positive reframe, helping to shift the user’s perspective.

“We are excited to introduce Grace to the world, as it offers a new way for individuals to manage their thoughts and emotions in a positive way,” said Rajiv Agarwal, the developer of Grace. “We believe that Grace has the potential to make a significant impact on mental health and overall well-being.”

Try it out for yourself and experience the power of positive reframing with Grace –


Rajiv Agarwal


Building & Construction Electronics & Semiconductors Science Technology U.K

Process Parameters Releases Wiring Guide for the Pt100 Temperature Sensor

Process Parameters Ltd is a manufacturer of thermocouples, thermistor sensors and platinum resistance thermometers (also known as RTDs and Pt100s) with many years of experience.

The company is committed to meeting the needs of its customers and providing top-quality products. It provides products that are excellent value for money, backed by the highest levels of service and technical support from experts.

Process Parameters’s products are suitable for a various industries, such as aerospace, automotive, biomass, construction, defence, electronics, food & beverage, foundries, and more. The company’s product selection and specifications meet a wide range of needs over the entire temperature range (including cryogenic temperatures for molten metals).

The company’s wiring guide for Pt100 temperature sensors allows users to understand the wiring process since, according to UK-based industrial temperature sensor experts, a Pt100 temperature sensor’s conductor material depends on the thermocouple’s application.

A Pt100 temperature sensor has special wiring compared to other temperature sensors, particularly thermocouples. Therefore, incorrect sensor wiring could result in an inaccurate measurement or no reading from the measuring device.

According to Process Parameters Ltd’s wiring guide, a Pt100 temperature sensor will allow people to avoid mistakes during the wiring process. However, most people become confused over the misleading term “Pt100 Thermocouple”, as such a sensor type does not exist. Furthermore, this term combines the names of two technologies. Therefore, when specifying a thermocouple or Pt100, it is critical to identify the type of sensor in use.

Process Parameters Ltd states that a Pt100 is a sensor used to measure temperature. One type of sensor falls into a group called Resistance Temperature Detectors or RTDs. Several factors determine the specification of Pt100 temperature sensors, and what follows will describe each factor and allow you to specify a Pt100 temperature sensor easily.

Consequently, a guide for sensor wiring is crucial to ensure that wiring is done correctly. This is because the measuring instrument may give an incorrect or no reading.

The experts at Process Parameters have experience in providing temperature measurement, control, and recording solutions for various industries. Process Parameters Ltd has been involved in product selection and specification to fulfil various equipment over the whole temperature range, from cryogenic temperatures to molten metals.

By offering guides and advice on Pt100 temperature sensors, Process Parameters Ltd aims to make the wiring process as simple as possible. This will ensure the job is done right the first time.

Process Parameters Ltd. states that the circumstances of the process will determine the cable needed to connect the sensor to the measuring unit. Many standard sensors include a flying wire directly attached to the instrument. This cable was carefully chosen to satisfy the application’s temperature requirements and other environmental factors.

Process Parameters Ltd has been in business for over 14 years and serves many clients, from small businesses to large blue-chip companies and universities. Process Parameters Ltd’s discerning and well-trained staff have years of experience in industrial temperature measurement and thermography.

More information can be found at

Science Technology U.K

Geothermal Monitoring: Silixa Introduces its Latest Cost-Effective Solution for Long-Term Reservoir Monitoring

Hertfordshire, UK, 20th Jan — Silixa, the leading provider of fibre optic sensing-based data solutions, has recently brought its high-end geothermal monitoring solution—The Carina® GeoTH—into action. 

The company hopes that its Carina® GeoTH will act as a step-change in the long-term monitoring of geothermal reservoirs. 

“Carina® GeoTH is a reliable and proven continuous monitoring solution that delivers reliable information on microseismic, induced seismicity, and well integrity assessment,” explains a spokesperson from Silixa. “It provides reliable long-term reservoir monitoring.”

By enabling sustainable and economic utilisation of the Earth’s natural heat, Carina® GeoTH efficiently speeds up the energy transition. With this permanently installed integrated fibre optic system, Silixa is committed to providing clean, affordable energy.

Silixa’s class-leading geothermal monitoring solution delivers high-fidelity data essential to ensuring reliable reservoir monitoring, improving reservoir efficiency and safely deploying EGS.

By operating optimally even in corrosive and high-temperature environments, the Carina® GeoTH offers a continuous and simultaneous understanding of mechanical, thermal and hydraulic properties in a field.

The system offers highly accurate and precise data on reservoir simulation, reservoir deformation caused by temperature and pressure variations, reservoir temperature evolution, fracture networks, and more. 

Silixa’s high-end geothermal monitoring solution uses a single fibre optic cable as the sensing element that can be cemented behind the reservoir casing or installed in shallow geothermal systems.

It’s a highly flexible system with large coverage—Carina® GeoTH can deliver on-demand and continuous data over a large distance. 

Plus, having Silixa’s Carina® Sensing System as the underlying technology, the Carina® GeoTH enables operators to monitor multiple geothermal wells effectively using a single interrogator.

Due to the system involving no moving or electronic parts, the maintenance and operation costs decrease significantly.

On top of that, by operating autonomously in remote locations, Carina® GeoTH limits human intervention while also ensuring optimised geothermal operations. 

Silixa’s Carina® GeoTH helps technicians efficiently constrain permeable fracture zones. By leveraging active or passive seismic methods with a spectrum of automated surface sources, they can efficiently keep track of fracture behaviour and evolution in a geothermal field. 

Equipped with a high-end optoelectronics interrogator and high-temperature sensing cables, Silixa’s geothermal monitoring system enables simultaneous measurement of DAS, DSS, and DTS. 

The data collected in this integrated approach to geothermal monitoring facilitates numerical modelling of site fracture permeability as well as the validation of hydro-geomechanical simulations. The result is optimised EGS (Enhanced Geothermal System) resources and efficient drilling of subsequent injection/production wells. 

In addition, the high-resolution distributed strain, temperature, and acoustic sensing data delivered by Silixa offer the finest high-spatial resolution measurements in each 0.12 to 1.0 metres along the optical fibre cable. As a result, operators can gain reliable and in-depth insight into the geothermal reservoir. 

Furthermore, the integrated Edge Processing System with Silixa’s geothermal monitoring solution enables real-time visualisation and processing of these distributed strain, acoustic, and temperature data that facilitates decision-making. 

Founded in 2007, Silixa is committed to helping the mining, oil and gas, alternative energy, and environmental and earth sciences industries address critical measurement challenges with its high-end fibre-optic solutions. 

Interested parties can learn more about Silixa’s Carina® GeoTH by visiting

Health & Medicine Pharmaceuticals & Biotech Science Technology U.S

Decentralization Plays a Key Role in Enhancing Oncological Care, Says ObvioHealth

New York, NY, Jan 20 — Leading Virtual research organization (VRO), ObvioHealth sheds light on the role of decentralized clinical trials(DCTs) in improving the quality of care for oncology patients.

“Extending the survivability of an illness is a key goal in the development of new medications, medical devices, and treatment protocols,” explains a spokesperson from ObvioHealth. “Increasing overall quality of care is an equally worthwhile objective. Incorporating DCT elements facilitates both goals.”

According to the VRO, conducting clinical trials is an effective way of improving the quality of life for cancer patients during and after treatment. However, clinical research in oncology isn’t reaching the patients who could benefit the most. 

Even though the barriers to clinical trial participation have been a topic of frequent research, no subsequent policy changes have shifted the paradigm enough to vastly change trial participation rates over time.  

Case in point: Clinical barriers (e.g., not meeting eligibility criteria) and structural barriers (e.g., the absence of an available clinical trial, travel cost, etc.) make trial participation unachievable for more than three-quarters of oncology patients, according to a study published in the Journal of the National Cancer Institute. 

For cancer patients with rare, irremediable, or life-threatening physical conditions, DCT designs can bring new care options by increasing their access to innovative therapeutics. 

However, due to having logistic constraints, full decentralization is not feasible for some types of clinical trials in the oncology space. 

Delivering drugs to a patient’s home, maintaining drug stability, and hiring certified nurses to administer drugs to patients at home are some of the constraints to oncology trial decentralization. 

Despite these hurdles, adopting DCT elements through hybrid trial models is rapidly gaining momentum. 

As a more patient-centric approach to oncology trials, DCTs can streamline trial processes while also significantly enhancing trial logistics. 

A DCT’s potential to facilitate access by eliminating geographic barriers to entry is a game-changer for cancer research and treatment. With DCTs in place, local oncologists can refer patients to trial screenings without overwhelming a small community hospital that can’t support centralized research.

The VRO highlights DCT and hybrid clinical studies as the way forward to reduce patient burden in oncology trials. 

Even though much of oncology research still requires on-site participation, specific appointments are more administrative than interventional and don’t need the one-on-one involvement of a physician.

Allowing participants to volunteer for trials from the comfort of their homes, DCTs minimize the need for in-person visits, thus decreasing patient burden substantially.

In addition, participants’ reluctance to report symptoms or hesitation to contact their trial support staff if they develop side effects can impact data quality and ultimately, the accuracy of trial endpoints. 

DCT solutions include convenient in-app messaging tools that help patients communicate with physicians and flag symptoms that they might otherwise consider insignificant.

On top of this, by enabling real-time reporting and communication, DCT solutions drive data quality and allow study teams to make evidence-based, data-driven decisions around the effect of a treatment on a participant’s quality of life.

Instead of capturing a brief snapshot of a patient’s health during a clinical visit, DCT solutions enable study teams to gain a longitudinal view of how their patients’ health may be trending. Continuous monitoring of risk factors, health outcomes, or both, based on the symptoms logged by patients with ePRO, helps sponsors make data-driven decisions about patient care.

To navigate challenges to success and extend access to life-improving treatments for cancer patients, adopting the modular approach (e.g., leveraging digital questionnaires or online recruitment) to oncology trials is critical, explains ObvioHelath.

Headquartered in New York, NY, ObvioHealth is a global digital health company committed to driving innovation in healthcare. With its tech-enabled nextGen DCT platforms, ObvioHelath helps sponsors effortlessly produce robust therapeutic evidence. 

Interested parties can find more information about ObvioHealth by visiting

Computers & Software Science Technology U.S

Sapio Sciences Rings in 2023 With Major Investment from GHO Capital

Baltimore, MD, Jan 6, 2023 — The London-based leading specialist healthcare investment advisor, Global Healthcare Opportunities, also called GHO Capital Partners LLP, has announced its investment in Sapio Sciences, a high-growth integrated lab informatics platform.

Lab informatics platforms are gaining momentum today, with more modern laboratories striving to accelerate their R&D. With GHO’s backing to scale it, Sapio Sciences hopes the company will evolve as a formidable player in the lab informatics market. 

Kevin Cramer, Chief Scientist and CEO at Sapio, said of GHO’s recent investment decision, “As lab workflows become increasingly complex and the volume of data increases, the management, and interrogation of that data becomes even more vital. Over the last eighteen years, Sapio has built a uniquely flexible, scalable, unified, and easy-to-use informatics platform developed specifically to address the deficiencies of current processes. We are proud to have GHO partner with us to support our next transformational steps as a company.”

Launched in 2004, Sapio Sciences is a US-based state-of-the-art lab informatics platform committed to transforming and speeding up life science R&D for biopharma, CROs, and clinical labs. 

This unified low-code/no-code platform offers various lab software products, such as its high-end scalable Electronic Lab Notebook (ELN), Laboratory Information Management System (LIMS), and Software Data Management (SDMS) software.

Sapio helps digital labs address all challenges they face while breaking through data silos and driving efficiency in their laboratory operations.

Sapio’s collaborative LIMS system allows multiple researchers to work on the same workflow simultaneously while also enabling rapid implementation of their workflow processes.

It’s the only informatics platform that provides digital labs with integrated ELN, LIMS, and SDMS with powerful data capture and searching tools.

Allowing laboratories to centralize data once siloed in multiple systems and making them effortlessly searchable and shareable among departments, Sapio streamlines the scientific discovery process.

With Sapio LIMS’s fully configurable technology and workflow templates, projects can be accomplished in a fraction of the time and cost of a standard lab management project. 

Validated by a broad and loyal customer base, including blue-chip companies across the USA with additional footholds in Japan and Europe, Sapio continues to help drive innovation in the ever-evolving lab informatics and pharmaceutical landscape. 

GHO’s investment, combined with its unrivaled experience, will support Sapio to drive growth for the company while facilitating its product development, says the private equity firm.

In addition, the firm’s investment into Sapio’s Commercial function and Business Development will help it establish a go-to-market strategy, thus uncovering significant white space in the market. 

To quote the Partners at GHO Capital, “The trend towards adopting lab informatics solutions is accelerating. Sapio represents a perfect opportunity to support a high-growth, profitable company with a uniquely scalable SaaS business model, operating in attractive markets that are underpenetrated and desperate for innovation. Working in lockstep with Kevin, we look forward to building upon Sapio’s best-in-class profile and unlocking the multiple expansion opportunities to scale up and internationalize the business, delivering life-changing products to market faster.”

Backed by eighteen years of experience, Sapio Sciences continues to remain a trusted and unbiased partner to its global clientele. 

Interested parties can learn more about Sapio Sciences by visiting